# FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026 In April 2026, the FDA announced it would remove 12 popular peptides from Category 2 restrictions including some of the most widely used compounds in biohacking, regenerative medicine, and peptide therapy circles
It works for all skin types, with no serious side effects reported in studies
(Innopeptides) Monitoring strategies Pre-treatment: full panel including CBC, kidney/liver, endocrine, inflammatory cytokines, baseline DEXA, body comp, visceral fat
show hepatoprotective effects on cholestatic mice by regulating enterohepatic circulation of bile acids
CJC-1295 (No DAC) 5mg A synthetic analog of growth hormonereleasing hormone designed without a Drug Affinity Complex, allowing researchers to study short-duration, pulsatile signaling patterns